STE · Healthcare

STERIS plc

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

10-Q · 2026-08-07

• Capital Return ProgramImportance 58 · Surprise 42
  STERIS repurchased 0.5 million ordinary shares for $100.0 million during the first three months of fiscal 2027 under the share-repurchase program adopted by the Board on May 5, 2026. No repurchases occurred under the…
• Segment Revenue PerformanceImportance 55 · Surprise 32
  Healthcare revenue increased 7.6% to $1,048.3 million, with service, consumable, and capital equipment revenue growth of 9.6%, 9.2%, and 1.4%, respectively. Constant-currency organic Healthcare growth was 6.4%, driven…
• Income Tax Rate ChangesImportance 52 · Surprise 56
  Income tax expense increased 34.5% to $72.5 million for the three months ended June 30, 2026, from $53.9 million. The effective income tax rate increased to 26.5% from 23.3%, a 3.2-percentage-point increase. The higher…
• Geographic Market CommentaryImportance 52 · Surprise 30
  United States revenue increased 6.3% to $1,090.6 million, reflecting growth in service, consumable, and capital equipment revenues. Ireland revenue increased 28.7% to $29.0 million, with growth across service, capital…
• Acquisition / Partnership / DivestitureImportance 50 · Surprise 58
  STERIS completed three tuck-in acquisitions during the first three months of fiscal 2027 to expand Healthcare products and services. Aggregate consideration was approximately $17.3 million, including deferred and…
• Gross Margin DriversImportance 49 · Surprise 32
  Gross profit increased 8.9% to $684.2 million for the three months ended June 30, 2026, from $628.0 million. Total gross margin expanded to 45.8% from 45.1%, while product gross margin increased to 50.0% from 47.9% and…
• Headcount / RestructuringImportance 46 · Surprise 42
  STERIS’s May 2024 restructuring plan eliminated approximately 300 positions and included a strategic shift in the European Healthcare surgical business, product rationalizations, and facility consolidations. The plan…
• Operating Income and MarginsImportance 45 · Surprise 40
  Income from operations increased 16.2% to $285.8 million for the first three months of fiscal 2027 from $246.0 million. The improvement was driven primarily by increased pricing, volume, and productivity, partly offset…
• Operating Cash Flow TrendsImportance 45 · Surprise 40
  Cash flow from operations declined 12.6% to $367.1 million in the first three months of fiscal 2027 from $420.0 million. Free cash flow declined 14.4% to $279.6 million from $326.5 million after $87.5 million of…
• Revenue Performance and MixImportance 43 · Surprise 32
  Total revenue increased 7.3% year over year to $1,492.7 million in the three months ended June 30, 2026, from $1,391.1 million. Service revenue rose 7.8% to $755.5 million, consumable revenue rose 9.0% to $474.0…
• Operating Expense TrendsImportance 42 · Surprise 14
  Total operating expenses increased 4.3% to $398.3 million in the first quarter of fiscal 2027 from $382.0 million. SG&A increased 4.5% to $369.7 million, primarily because of higher compensation and benefits and…
• Trade Policy and TariffsImportance 40 · Surprise 42
  Net tariffs contributed a favorable 20 basis points to STERIS’s consolidated gross profit percentage in the three months ended June 30, 2026. The company’s corporate operating-cost reconciliation includes refunds…
• Manufacturing Capacity ExpansionImportance 37 · Surprise 42
  On August 5, 2026, STERIS announced a targeted restructuring plan to consolidate formulated-chemistry manufacturing and distribution at a new Center of Excellence in North Carolina. The plan anticipates closing…
• Liquidity and Debt PositionImportance 31 · Surprise 6
  STERIS’s debt-to-total-capital ratio was 20.9% at June 30, 2026, down from 21.5% at June 30, 2025. Net payments under credit facilities were $37.8 million in the first three months of fiscal 2027, compared with $30.5…
• Inflation Cost PressureImportance 20 · Surprise 24
  Inflation reduced STERIS’s consolidated gross profit percentage by 60 basis points in the three months ended June 30, 2026, partially offsetting pricing, productivity, and mix benefits. Healthcare operating income was…
• Products and TechnologyImportance 6 · Surprise 6
  STERIS provides infection-prevention products and services across healthcare, medical device, and pharmaceutical markets, including consumables, sterilizers, surgical tables, automated endoscope reprocessors,…

News · 2026-08-07

• Revenue Performance and MixImportance 24 · Surprise 14
  STERIS reported fiscal Q1 2027 revenue of $1,492.7 million for the quarter ended June 30, 2026, up 7.3% from $1,391.1 million a year earlier. Net income increased to $200.1 million from $177.4 million, while diluted…

News · 2026-08-06

• Manufacturing and CapacityImportance 52 · Surprise 42
  STERIS plans to invest $600 million in a 600,000-square-foot Formulated Chemistries Center of Excellence near Raleigh-Durham, North Carolina. The campus will manufacture and distribute chemistries used by global…
• Guidance / OutlookImportance 44 · Surprise 24
  STERIS reaffirmed its fiscal 2027 revenue and adjusted earnings-per-share guidance after reporting first-quarter results. Management expects the North Carolina chemistry investment to generate a significant return on…
• Revenue Performance and MixImportance 24 · Surprise 14
  STERIS reported fiscal Q1 2027 revenue of $1,492.7 million for the quarter ended June 30, 2026, up 7.3% from $1,391.1 million a year earlier. Net income increased to $200.1 million from $177.4 million, while diluted…
• Market Demand TrendsImportance 20 · Surprise 24
  Analysts are monitoring destocking in STERIS's Applied Sterilization Technologies (AST) segment for signs of stabilization. The concern centers on weaker or uneven demand from medical-technology customers and a…

8-K · 2026-08-05

• Capital Expenditure OutlookImportance 85 · Surprise 76
  Fiscal 2027 capital expenditures are now expected to be approximately $450 million, up from the prior estimate of $375 million. The $75 million increase reflects the investment to build the formulated chemistries…
• Guidance / OutlookImportance 85 · Surprise 76
  STERIS reiterated its fiscal 2027 revenue and earnings guidance, including reported revenue growth of 7% to 8%, constant-currency organic revenue growth of 6% to 7%, and adjusted diluted EPS of $11.10 to $11.30.…
• Capital Return ProgramImportance 63 · Surprise 64
  STERIS repurchased $115.5 million of ordinary shares in the first quarter of fiscal 2027, compared with $10.6 million in the prior-year quarter. Cash dividends paid to ordinary shareholders increased to $61.4 million…
• Restructuring and Facility ConsolidationImportance 52 · Surprise 42
  STERIS announced a targeted restructuring plan tied to a new Formulated Chemistries Center of Excellence in North Carolina. The plan anticipates closing chemistry manufacturing and distribution facilities in St. Louis,…
• Market Demand TrendsImportance 49 · Surprise 32
  STERIS reported stable underlying demand in fiscal 2027 first quarter, with total revenue increasing 7% and constant-currency organic revenue growing 6%. Healthcare revenue grew 8%, including 10% service growth and 9%…
• Products and TechnologyImportance 49 · Surprise 32
  Recurring products and services drove the company’s growth, with total consumables revenue increasing from $435.0 million to $474.0 million and service revenue increasing from $700.6 million to $755.5 million.…
• Segment ProfitabilityImportance 47 · Surprise 22
  Healthcare operating income increased to $260.2 million from $235.5 million, supported by improved volume, price, productivity, and favorable mix. Healthcare margin increased to approximately 24.8% from 24.2%, despite…
• Operating Cash Flow TrendsImportance 47 · Surprise 22
  Net cash provided by operating activities declined to $367.1 million from $420.0 million, a decrease of $52.9 million or 12.6%. Free cash flow declined to $279.6 million from $326.5 million, a decrease of $46.9 million…
• Liquidity and Debt PositionImportance 47 · Surprise 14
  Cash and cash equivalents increased to $482.3 million at June 30, 2026, from $439.6 million at March 31, 2026. Short-term indebtedness increased to $243.4 million from $118.9 million, while long-term indebtedness…
• Income Tax Rate ChangesImportance 45 · Surprise 38
  Income tax expense increased to $72.5 million from $53.9 million, an increase of $18.6 million or 34.5%. The reported income tax rate increased to 26.5% from 23.3%, while the adjusted income tax rate increased to 25.9%…
• Revenue Performance and MixImportance 42 · Surprise 14
  Fiscal 2027 first-quarter revenue increased 7.3% year over year to $1,492.7 million from $1,391.1 million, while constant-currency organic revenue growth was 6.2%. Recurring revenue increased to $1,229.6 million from…
• Gross Margin DriversImportance 42 · Surprise 14
  Gross profit increased to $684.2 million from $628.0 million, a year-over-year increase of $56.2 million or 8.9%. Consolidated gross margin increased to approximately 45.8% from 45.1%, an improvement of about 70 basis…
• Operating Expense TrendsImportance 42 · Surprise 14
  Selling, general, and administrative expense increased to $369.7 million from $353.8 million, an increase of $15.9 million or 4.5%. Research and development expense increased to $28.6 million from $26.4 million, an…
• Manufacturing and CapacityImportance 34 · Surprise 42
  STERIS is consolidating formulated-chemistries manufacturing and distribution into a new Center of Excellence in North Carolina. The company stated that the facility is intended to accelerate innovation, expand…
• Acquisition / Partnership / DivestitureImportance 34 · Surprise 42
  STERIS announced a targeted restructuring plan to consolidate formulated-chemistries manufacturing and distribution at a new Center of Excellence in North Carolina. The initiative is intended to accelerate innovation,…

News · 2026-08-05

• Capital Expenditures and Free Cash FlowImportance 62 · Surprise 58
  STERIS increased its fiscal 2027 capital expenditure outlook to reflect the $600 million North Carolina chemistry campus investment. Fiscal Q1 free cash flow declined 14.4% year over year because of a smaller…
• North Carolina Chemistry InvestmentImportance 52 · Surprise 42
  STERIS plans to invest $600 million in a 600,000-square-foot Formulated Chemistries manufacturing and distribution Center of Excellence near Raleigh-Durham, North Carolina. The campus will support sterilization and…
• Manufacturing and CapacityImportance 52 · Surprise 42
  STERIS plans to invest $600 million in a 600,000-square-foot Formulated Chemistries Center of Excellence near Raleigh-Durham, North Carolina. The campus will manufacture and distribute chemistries used by global…
• Manufacturing Capacity ExpansionImportance 52 · Surprise 42
  STERIS plans to invest $600 million in a 600,000-square-foot Formulated Chemistries Center of Excellence near Raleigh-Durham, North Carolina. The campus will support sterilization and disinfection chemicals for global…
• Headcount / RestructuringImportance 46 · Surprise 42
  STERIS is consolidating formulated chemistries manufacturing and distribution into the new North Carolina Center of Excellence. The plan is expected to close facilities in St. Louis, Missouri, and Plymouth, Minnesota,…
• Guidance / OutlookImportance 44 · Surprise 24
  STERIS reaffirmed its fiscal 2027 revenue and adjusted earnings-per-share guidance after reporting first-quarter results. Management expects the North Carolina chemistry investment to generate a significant return on…
• Revenue Performance and MixImportance 24 · Surprise 14
  STERIS reported fiscal Q1 2027 revenue of $1,492.7 million for the quarter ended June 30, 2026, up 7.3% from $1,391.1 million a year earlier. Net income increased to $200.1 million from $177.4 million, while diluted…
• Market Demand TrendsImportance 20 · Surprise 24
  Analysts are monitoring destocking in STERIS's Applied Sterilization Technologies (AST) segment for signs of stabilization. The concern centers on weaker or uneven demand from medical-technology customers and a…
• Dividend IncreaseImportance 18 · Surprise 14
  STERIS increased its quarterly dividend to $0.69 per share from $0.63 per share. The increase represents the company's 21st consecutive annual dividend increase. The higher dividend was reported alongside fiscal Q1…

News · 2026-08-04

• Guidance / OutlookImportance 44 · Surprise 24
  STERIS reaffirmed its fiscal 2027 revenue and adjusted earnings-per-share guidance after reporting first-quarter results. Management expects the North Carolina chemistry investment to generate a significant return on…